PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

21st Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 8th October 2024 (Educational supporters)

LDL binding to the LDL receptor: Structural insights

LDL binding to the LDL receptor: Structural insights

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Alan Remaley

Posted on 19 December 2024 | Posted by Alan Remaley | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board

AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data

AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Rick Vega

Posted on 23 October 2024 | Posted by Rick Vega | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board

Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme

Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Dirk Blom

Posted on 23 October 2024 | Posted by Dirk Blom | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board

The trajectory of ASCVD: Focus on subclinical atherosclerosis

The trajectory of ASCVD: Focus on subclinical atherosclerosis

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Borja Ibanez

Posted on 23 October 2024 | Posted by Borja Ibanez | Posted in Hot topics, 21st Closed Scientific Expert Meeting of the Editorial Board

Lipid and lipoprotein genes: More data, more complexity

Lipid and lipoprotein genes: More data, more complexity

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Catherine Boileau

Posted on 23 October 2024 | Posted by Catherine Boileau | Posted in 21st Closed Scientific Expert Meeting of the Editorial Board

Very low LDL-C: Long-term prospective findings

Very low LDL-C: Long-term prospective findings

Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Michelle O’Donoghue

Posted on 23 October 2024 | Posted by Michelle O'Donoghue | Posted in 21st Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved